Petros Grivas, MD, PhD, on Updates in Genitourinary Oncology From ASCO 2021

Video

Petros Grivas, MD, PhD, regarding updates in genitourinary oncology that were read out at the meeting.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Petros Grivas, MD, PhD, regarding updates in genitourinary oncology that were read out at the meeting

Among the numerous trials that were presented, the phase 3 VISION trial (NCT03511664), which examined lutetium-177-PSMA-617 (Lutathera) in patients with metastatic castration-resistant prostate cancer, was particularly important.1 Additionally, the phase 3 KEYNOTE-564 trial (NCT03142334), which examined adjuvant pembrolizumab (Keytruda) in resected renal cell carcinoma (RCC), yielded interesting data, according to Grivas.2

Transcript:

We had the opportunity to see amazing presentations at the ASCO 2021 Virtual Meeting. It is definitely difficult to summarize everything in a few minutes, but definitely the plenary session presentations, [no] doubt, [were important]. The lutetium [prostate-specific membrane antigen; PSMA] data from the randomized clinical trial that Michael J. Morris, MD, [of Memorial Sloan Kettering Cancer Center] presented at the ASCO plenary session [were] definitely very important. It is very likely to be practice changing. Here at Seattle Cancer Care Alliance, we are working on having PSMA-PET scans available for our patients, either for clinical trials or as a standard of care down the road.

It is very likely that this lutetium-177-PSMA-617 radiopharmaceutical is likely to be an approved option down the road. The data from Moore’s [presentation] substantiate that argument. Also very interesting [were the] data from Toni Choueiri, [MD] of Dana-Farber Cancer Institute in the adjuvant setting in patients with resected RCC. [In] adjuvant kidney cancer, pembrolizumab [demonstrated] disease-free survival benefit vs the control group. That is a very important dataset. There was a trend that the overall survival [OS] might also be beneficial, but the OS data were not mature yet. In that particular dataset, we have to wait to see OS in the adjuvant [setting]. The data I’m referring to [are from] the KEYNOTE-564 trial, [which was] also presented [during] the plenary session. We will have to see whether the FDA will review and approve adjuvant pembrolizumab in resected kidney cancer

Reference

  1. Morris MJ, De Bono JS, Chi KN, et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). J Clin Oncol. 2021;39(suppl 15):LBA4. doi:10.1200/JCO.2021.39.15_suppl.LBA4
  2. Choueiri TK, Quinn DI, Zhang T, et al. KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma. J Clin Oncol. 2021;36(suppl 15):TPS4599. doi:10.1200/JCO.2018.36.15_suppl.TPS4599

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Related Content